144 / 144
144
PERGUNTAS & RESPOSTAS
EMD
- Edema Macular Diabético
Estudos pré-clínicos em modelos animais demonstraram alguma e%cácia na
inibição de achados iniciais da retinopatia diabética
14
. Está actualmente a ser
testado em ensaios de fase I para o edema macular diabético e fase II para a
DMI (NCT02314299)
Referências
1. Blindbaek SL,Torp TL, Lundberg K et al. Non invasive retinal biomarkers in diabetic
retinopathy: advancing from Bench towards Bedside. Journal of Diabetic Research, Vol
2017, Article ID2562759, 10 pages, 2017. doi:10.1155/2017/2562759
2. Agarwal A, Ingham SA, Harkins KA et al. The role of pharmacogenetics and advan-
ces in gene therapy in the treatment of diabetic retinopathy. Pharmacogenomics.
2016;17(3):309-320.
3. Sakuma T, Mizota A, Inoue J, Tanaka M. Intravitreal injection of autologous plas-
min enzyme for macular edema associated with branch retinal vein occlusion. Am J
Ophthalmol. 2010 Dec;150(6):876-82.
4. Kaiser PK, Kampik A, Kuppermann BD, Girach A, Rizzo S, Sergott RC. Safety pro%le of
ocriplasmin for the pharmacologic treatment of symptomatic vitreomacular adhesion/
traction. Retina. 2015;35(6):1111-1127.
5. Novack RL, Staurenghi G, Girach A, Narendran N, Tolentino M. Safety of intravitreal
ocriplasmin for focal vitreomacular adhesion in patients with exudative age-related
macular degeneration. Ophthalmology. 2015;122(4):796-802.
6. Quiram PA, Leverenz VR, Baker RM, et al. Microplasmin induced posterior vitreous
detachment affects vitreous oxygen levels. Retina
2007;27:1090-1096
.
7. Pessoa B, Coelho J, Monteiro S et al. Safety and Ef%cacy of Intravitreal Ocriplasmin
in Diabetic Macular Edema with Vitreomacular Adhesion,
EVRS – presentation, 2016.
8. Coelho J, Pessoa B, Correia N et al. Safety and Ef%cacy of Intravitreal Ocriplasmin
in Diabetic Macular Edema with Vitreomacular
Adhesion – results of a guided intravitreal injection method, ARVO –
Poster 3700 - B0325, 2017.
9. Luo W, Xie F, Zhang Z, et al. Vascular adhesion protein 1 in the eye. J. Ophthalmol.
2013;2013:925267. doi: 10.1155/2013/925267
10. Kita T, Clermont AC, Murugesan N et al. Plasma kallikrein-Kinin system as VEGF-Inde-
pendent mediator of diabetic macular edema. Diabetes. 2015;64:3588-3599.
11. Poulaki V, Joussen AM, Mitsides N, Mitsides CS, Iliaki EF, Adamis AP. Insulin-like
Growth Factor-I plays a pathogenetic role in diabetic retinopathy. Am J Pathol. 2004
Aug;165(2):457-69.
12. Wang Q, Dills DG, Klein R et al. Does Insulin-like factor I predict incidence and pro-
gression of diabetic retinopathy? Diabetes. 1995;44(2):161-164.
13. Schopf L, Enlow E, Popov A, Bourassa J, Chen H. Ocular pharmacokinetics of a novel
loteprednol etabonate 0,4% ophthalmic formulation. Ophthalmol Ther. 2014;3(1-
2):63-72.
14. Alam NM, Mills WC, Wong AA, et al. A mitochondrial therapeutic reverses visual decli-
ne in mouse model of diabetes. Dis Model Mech. 2015;504(1):56-60.